Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins

preview_player
Показать описание
Presented By: Shannon K. Oda, PhD

Speaker Biography: Dr. Shannon Oda earned a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center. She has received several awards, including the Evergreen Fund Award and the LLS Career Development Program Special Fellow Award, and has been invited to give talks internationally.

Webinar: Overcoming cell therapy barriers in the suppressive tumor microenvironment with engineered proteins

Webinar Abstract: Adoptive cell immunotherapy (ACT) with genetically-modified T cells has shown impressive efficacy against some cancers, particularly CD19+ leukemias. However, ACT efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs), with increased inhibitory signals, reduced T cell infiltration/accumulation, and inadequate metabolic substrates. FasL is a death receptor ligand that is overexpressed in the majority of human TMEs and can protect tumor cells from immunity.

Earn PACE Credits:

LabRoots on Social:
SnapChat: labroots_inc
Рекомендации по теме